S. L. Aronson, Marta Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, Mignon D.J.M. van Gent, H. Arts, M. van Ham, Peter A. van Dam, Peter Vuylsteke, A. Aalbers, V. Verwaal, K. K. Van de Vijver, Neil K. Aaronson, G. Sonke, W. V. van Driel
{"title":"晚期卵巢癌患者接受或不接受热疗腹膜内化疗的去细胞手术（OVHIPEC-1）：随机对照 3 期试验的最终生存率分析","authors":"S. L. Aronson, Marta Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, Mignon D.J.M. van Gent, H. Arts, M. van Ham, Peter A. van Dam, Peter Vuylsteke, A. Aalbers, V. Verwaal, K. K. Van de Vijver, Neil K. Aaronson, G. Sonke, W. V. van Driel","doi":"10.1097/01.ogx.0001008536.08634.9f","DOIUrl":null,"url":null,"abstract":"(Abstracted from Lancet Oncol 2023;24:P1109–P1118)\n Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.","PeriodicalId":509854,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"10 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial\",\"authors\":\"S. L. Aronson, Marta Lopez-Yurda, S. Koole, J. H. Schagen van Leeuwen, H. W. Schreuder, R. Hermans, I. D. de Hingh, Mignon D.J.M. van Gent, H. Arts, M. van Ham, Peter A. van Dam, Peter Vuylsteke, A. Aalbers, V. Verwaal, K. K. Van de Vijver, Neil K. Aaronson, G. Sonke, W. V. van Driel\",\"doi\":\"10.1097/01.ogx.0001008536.08634.9f\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(Abstracted from Lancet Oncol 2023;24:P1109–P1118)\\n Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.\",\"PeriodicalId\":509854,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":\"10 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.ogx.0001008536.08634.9f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0001008536.08634.9f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial
(Abstracted from Lancet Oncol 2023;24:P1109–P1118)
Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
